Genprex (GNPX)

Company Profile

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company's lead product candidate, REQORSA™ (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca's Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone.

Company profile

Ticker

GNPX

Exchange

NASDAQ

Website

www.genprex.com

CEO

J. Rodney Varner

Incorporated

Texas

Location

Texas

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Celgene ...

SEC CIK

0001595248

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

GNPX stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

8-K

Regulation FD Disclosure

6 Jan 23

8-K

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

28 Nov 22

8-K

Regulation FD Disclosure

21 Nov 22

424B5

Prospectus supplement for primary offering

18 Nov 22

8-K

Entry into a Material Definitive Agreement

14 Nov 22

Regulation FD Disclosure

21 Oct 22

8-K

Regulation FD Disclosure

11 Oct 22

Latest ownership filings

View all

Toscano Jose Antonio Moreno

Financial summary

Financial statements Chart GNPX financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	25.52 mm	25.52 mm	25.52 mm	25.52 mm	25.52 mm	25.52 mm
Cash burn (monthly)	1.51 mm	1.38 mm	2.04 mm	1.89 mm	1.52 mm	1.37 mm
Cash used (since last report)	6.16 mm	5.60 mm	8.30 mm	7.70 mm	6.21 mm	5.57 mm
Cash remaining	19.36 mm	19.91 mm	17.22 mm	17.81 mm	19.31 mm	19.95 mm
Runway (months of cash)	12.8	14.5	8.5	9.4	12.7	14.6

Beta Read what these cash burn values mean

Financial data from Genprex earnings reports.

Institutional ownership, Q3 2022

GNPX institutional ownership history Ownership history

8.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	43	43	–
Opened positions	7	1	+600.0%
Closed positions	7	10	-30.0%
Increased positions	11	10	+10.0%
Reduced positions	4	12	-66.7%

13F shares	Current	Prev Q	Change
Total value	6.11 mm	6.25 mm	-2.3%
Total shares	4.24 mm	4.40 mm	-3.8%
Total puts	65.00 k	75.50 k	-13.9%
Total calls	149.00 k	203.20 k	-26.7%
Total put/call ratio	0.4	0.4	+17.4%

Largest owners	Shares	Value	Change
Vanguard	1.83 mm	$2.57 mm	+0.0%
BLK Blackrock	562.99 k	$795.00 k	-2.6%
Geode Capital Management	440.66 k	$621.00 k	+2.0%
UBS UBS Group AG - Registered Shares	280.33 k	$395.00 k	+3.2%
Millennium Management	143.77 k	$203.00 k	+11.5%
Group One Trading	140.02 k	$197.00 k	-11.1%
Verus Capital Partners	90.50 k	$128.00 k	+1.1%
NTRS Northern Trust	75.40 k	$106.00 k	0.0%
Renaissance Technologies	73.56 k	$104.00 k	NEW
T. Rowe Price	67.50 k	$96.00 k	-16.0%

Largest transactions	Shares	Bought/sold	Change
STT State Street	0.00	-129.74 k	EXIT
Cypress Capital	0.00	-100.00 k	EXIT
Renaissance Technologies	73.56 k	+73.56 k	NEW
Spire Wealth Management	0.00	-45.00 k	EXIT
HighTower Advisors	0.00	-32.08 k	EXIT
Virtu Financial	0.00	-29.71 k	EXIT
Simplex Trading	22.76 k	+22.76 k	NEW
GS Goldman Sachs	0.00	-21.39 k	EXIT
Jane Street	19.93 k	+19.93 k	NEW
Tower Research Capital	20.99 k	+19.20 k	+1073.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GNPX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
28 Jul 22	Ryan M. Confer	Common Stock	Option exercise	Acquire M	No	No	0.015	116,973	1.75 k	190,499
28 Jul 22	Ryan M. Confer	Stock Option Common Stock	Option exercise	Dispose M	No	No	0.015	116,973	1.75 k	0
23 Jun 22	Brent M Longnecker	Stock Option Common Stock	Grant	Acquire A	No	No	1.36	83,368	113.38 k	83,368
23 Jun 22	William R Jr. Wilson	Stock Option Common Stock	Grant	Acquire A	No	No	1.36	83,368	113.38 k	83,368
23 Jun 22	Toscano Jose Antonio Moreno	Stock Option Common Stock	Grant	Acquire A	No	No	1.36	83,368	113.38 k	83,368
23 Jun 22	Hermant Kumar	Stock Option Common Stock	Grant	Acquire A	No	No	2.85	75,000	213.75 k	75,000